Search results
Showing 251 to 300 of 1957 results for news
OCU400 for treating retinitis pigmentosa in people 5 years and over [PDID6687]
Awaiting development Reference number: GID-TA11905 Expected publication date: TBC
and clinical indicators of late-onset infection: What is the accuracy of new or existing clinical prediction models for late-onset...
Topical tapinarof for treating mild to severe plaque psoriasis [ID6712]
Awaiting development Reference number: GID-TA11951 Expected publication date: TBC
Awaiting development Reference number: GID-TA11942 Expected publication date: TBC
This quality standard covers preventing dementia, and assessment, management and health and social care support for people with dementia. It describes high-quality care in priority areas for improvement.
View quality statements for QS184Show all sections
Sections for QS184
- Quality statements
- Quality statement 1: Raising awareness – health promotion interventions
- Quality statement 2: Diagnosis
- Quality statement 3: Advance care planning
- Quality statement 4: Coordinating care
- Quality statement 5: Activities to promote wellbeing
- Quality statement 6: Managing distress
- Quality statement 7: Supporting carers
Rusfertide for treating polycythaemia vera in people having phlebotomy [ID6709]
Awaiting development Reference number: GID-TA11937 Expected publication date: TBC
Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [ID6720]
Awaiting development Reference number: GID-TA11874 Expected publication date: TBC
technologies sometimes require new healthcare infrastructure or redesigned services to support their implementation. For example,...
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
View recommendations for AMR1Show all sections
Xanomeline tartrate–trospium chloride for treating schizophrenia [TSID12311]
Awaiting development Reference number: GID-TA11925 Expected publication date: TBC
Etavopivat for treating sickle cell disease in people 12 years and over [ID6698]
Awaiting development Reference number: GID-TA11912 Expected publication date: TBC
Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]
Awaiting development Reference number: GID-TA11930 Expected publication date: TBC
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6708]
Awaiting development Reference number: GID-TA11953 Expected publication date: TBC
This guideline covers diagnosing and managing gallstone disease in adults. It aims to reduce variation in care by promoting the most effective treatments, and to improve the advice given to people with gallstone disease before and after treatment.
Awaiting development Reference number: GID-TA11911 Expected publication date: TBC
Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [TSID12323]
Awaiting development Reference number: GID-TA11916 Expected publication date: TBC
Awaiting development Reference number: GID-TA11921 Expected publication date: TBC
Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314]
Awaiting development Reference number: GID-TA11917 Expected publication date: TBC
Awaiting development Reference number: GID-TA11932 Expected publication date: TBC
Zasocitinib for treating moderate to severe plaque psoriasis [ID6700]
Awaiting development Reference number: GID-TA11926 Expected publication date: TBC
Awaiting development Reference number: GID-TA11929 Expected publication date: TBC
NICE health technology evaluation topic selection: the manual (PMG37)
This manual sets out the process for deciding how topics are identified, selected and routed for NICE guidance developed by the Centre for Health Technology Evaluation (CHTE). This includes diagnostics, highly specialised technologies, interventional procedures, medical technologies and technology appraisal guidance
Stakeholder registration: guidelines, quality standards and indicators
How to register as a stakeholder to help us develop guidelines, quality standards and indicators.
Stakeholder registration: guidelines, quality standards and indicators
How to register as a stakeholder to help us develop guidelines, quality standards and indicators.
This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical modalities, and the impact of acne vulgaris on mental health and wellbeing.
Highly specialised technology (HST) evaluations are recommendations on the use of new and existing highly specialised medicines and treatments within the NHS in England.
People's experience using adult social care services (QS182)
This quality standard covers the experience of adults using social care services. It applies to all settings where people use social care services, including people's own homes, residential care and community settings. Its aim is to help people understand what care they can expect and to improve their experience by supporting them to make decisions about their care. It describes high-quality care in priority areas for improvement.
View quality statements for QS182Show all sections
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)
Evidence-based recommendations on pralsetinib (Gavreto) for treating RET fusion-positive advanced non-small-cell lung cancer in adults.
Health Technology Assessment Innovation Laboratory (HTA Lab)
NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.
Older people with social care needs and multiple long-term conditions (NG22)
This guideline covers planning and delivering social care and support for older people who have multiple long-term conditions. It promotes an integrated and person-centred approach to delivering effective health and social care services.
We've recently launched a new NICE website. Following a content review, a number of pages and sections have not moved onto the...
Abaloparatide for treating osteoporosis after menopause (TA991)
Evidence-based recommendations on abaloparatide (Eladynos) for treating osteoporosis after menopause in women, trans men and non-binary people with a very high risk of fracture.
face-to-face clinics:- What is the clinical and cost effectiveness of virtual new patient fracture clinics compared with next-day...
Dementia: assessment, management and support for people living with dementia and their carers (NG97)
This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)
Evidence-based recommendations on gilteritinib (Xospata) for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults.
Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
Evidence-based recommendations on using coronary artery stents in adults.
This guideline covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check-ups, information and support.
This guideline covers support for adults (aged 18 and over) who provide unpaid care for anyone aged 16 or over with health or social care needs. It aims to improve the lives of carers by helping health and social care practitioners identify people who are caring for someone and give them the right information and support. It covers carers’ assessments, practical, emotional and social support and training, and support for carers providing end of life care.
This guide describes the process NICE uses to develop NICE quality standards
of breast cancer. Studies should include sub-analysis for breast density. [new 2013] Any explanatory notes(if applicable) Why this is...
Behaviour change: digital and mobile health interventions (NG183)
This guideline covers interventions that use a digital or mobile platform to help people eat more healthily, become more active, stop smoking, reduce their alcohol intake or practise safer sex. The interventions include those delivered by text message, apps, wearable devices or the internet. The guideline only includes those that are delivered by the technology itself and not by healthcare professionals using technology to deliver interventions.
This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.
In development Reference number: GID-IPG10067 Expected publication date: TBC
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
Awaiting development Reference number: GID-TA11215 Expected publication date: 07 May 2026
How to register with us as a diagnostic technologies stakeholder.
How to register with us as a diagnostic technologies stakeholder.
Suspected sepsis in under 16s: recognition, diagnosis and early management (NG254)
This guideline covers the recognition, diagnosis and early management of suspected sepsis in under 16s (not pregnant or recently pregnant). It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction (HTG518)
Evidence-based recommendations on valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for aortic bioprosthetic valve dysfunction in adults. This involves placing a new bioprosthetic valve inside a failing bioprosthetic valve.
View recommendations for HTG518Show all sections
We've recently launched a new NICE website. Following a content review, a number of pages and sections have not moved onto the...